Prof. Giuseppe Curigliano, MD, PhD, Director of the Early Drug Development Division and Co-chair for Experimental Therapeutics Program at the European Institute of Oncology, Milan, Professor of Medical Oncology at the University of Milan, Italy will be the ESMO President 2027-2028.
“ESMO should lead the way in decoding cancer complexity to prevent and cure cancer through science and education, transforming patient and survivor outcomes beyond geographical boundaries,” Curigliano stated. “As ESMO President, my mission will be to overcome current challenges in integrating diverse oncology disciplines through a comprehensive plan focused on education and inclusivity toward global progress in cancer care.”
Curigliano is committed to establishing an ESMO hub dedicated to fostering opportunities for and advancing careers of young oncologists. “By creating a dedicated platform within ESMO, involving various stakeholders – including academia and industry, we aim to pioneer a paradigm shift,” Curigliano added. “This transformative approach would offer tangible opportunities, equalizing the playing field for talented oncologists worldwide. It would serve as a trusted resource for young oncologists' career development, providing mentorship and support.”
Curigliano will also empower ESMO’s efforts at the policy level to deliver real impact, by advancing global cancer research and prevention and coordinating the Society’s engagement in global cancer control.
“I am deeply committed to fostering a culture of continuous learning and professional development, ensuring that oncologists worldwide have access to the latest knowledge and resources.” Curigliano in fact believes the Society should continue investing in cultivating a global community of oncology professionals dedicated to making a meaningful difference in the lives of patients and families affected by cancer.
Curigliano has been engaged in ESMO for many years. He served as Chair of the ESMO Nomination Committee (2018-2021) and as Chair of the ESMO Clinical Practice Guidelines Committee (2020-2023). He was one of the initiators and served as Scientific Co-Chair of the “ESMO Breast Cancer Congress”. He contributed to the launch of the ESMO Living Guidelines and of the Fellow of ESMO (FESMO) programme. He organised and participated in many professional and educational programmes for oncologists all over the world. Currently, he is serving as Editor-in-Chief of ESMO Open.
Throughout his career, Curigliano has been involved in numerous breast and early development clinical trials, especially with innovative targeted compounds and individualised treatment strategies, and has authored over 670 peer-reviewed papers and many book chapters.
“Moving forward, it is crucial that ESMO continues advancing its mission of promoting excellence in the field of medical oncology to ensure optimal care for patients with cancer worldwide. I will remain steadfast in my dedication to fostering collaboration among multidisciplinary oncology experts, advocating for evidence-based practices, and championing innovative approaches to cancer treatment and research.”
As ESMO President-Elect 2025-2026, Curigliano will take seat on the ESMO Executive Board as of 1 January 2025.